Vermillion targets $31.5M from funding round

05/10/2013 | GenomeWeb Daily News (free registration)

Austin, Texas-based molecular diagnostics firm Vermillion hopes to raise as much as $31.5 million through the sale of 8 million shares of stock. Part of the proceeds will go toward improving sales and reimbursements for the company's OVA1 assay, which is used to distinguish malignant from benign ovarian tumors.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ